The Senate recently approved an amended version of S. 483, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015.  The bill, which was approved on March 17, 2016, would clarify the standards an applicant to manufacture or distribute controlled substances must meet in order to obtain a Controlled Substances Act registration, and the circumstances under which such a registration may be suspended.  According to the bill’s sponsor, Senator Orrin Hatch, the legislation “takes a balanced approach to the problem of prescription drug abuse by clarifying penalties for manufacturing or dispensing outside approved procedures while helping to ensure that supply chains to legitimate users remain intact.”